163 related articles for article (PubMed ID: 28972249)
21. Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labelling-based or mitotic activity index-based proliferation assessment.
Finsterbusch K; Decker T; van Diest PJ; Focke CM
Histopathology; 2020 Apr; 76(5):650-660. PubMed ID: 31846096
[TBL] [Abstract][Full Text] [Related]
22. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
[TBL] [Abstract][Full Text] [Related]
23. Expression of vimentin in breast carcinoma, its correlation with Ki67 and other histopathological parameters.
Hemalatha A; Suresh TN; Kumar ML
Indian J Cancer; 2013; 50(3):189-94. PubMed ID: 24061457
[TBL] [Abstract][Full Text] [Related]
24. Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count.
Lehr HA; Hansen DA; Kussick S; Li M; Hwang H; Krummenauer F; Trouet S; Gown AM
Hum Pathol; 1999 Nov; 30(11):1314-20. PubMed ID: 10571511
[TBL] [Abstract][Full Text] [Related]
25. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody.
Weidner N; Moore DH; Vartanian R
Hum Pathol; 1994 Apr; 25(4):337-42. PubMed ID: 8163266
[TBL] [Abstract][Full Text] [Related]
26. Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable.
Morimoto M; Bando Y; Nakagawa M; Takechi H; Yoshida T; Honda J; Tadokoro Y; Moriya T; Sasa M; Tangoku A
Breast Cancer; 2016 Jul; 23(4):577-82. PubMed ID: 25808597
[TBL] [Abstract][Full Text] [Related]
27. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
[TBL] [Abstract][Full Text] [Related]
28. Mitotic counts provide additional prognostic information in grade II mammary carcinoma.
Lynch J; Pattekar R; Barnes DM; Hanby AM; Camplejohn RS; Ryder K; Gillett CE
J Pathol; 2002 Mar; 196(3):275-9. PubMed ID: 11857489
[TBL] [Abstract][Full Text] [Related]
29. Practical issues concerning the implementation of Ki-67 proliferative index measurement in breast cancer reporting.
Harvey J; Thomas C; Wood B; Hardie M; Dessauvagie B; Combrinck M; Frost FA; Sterrett G
Pathology; 2015 Jan; 47(1):13-20. PubMed ID: 25474507
[TBL] [Abstract][Full Text] [Related]
30. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer.
Stålhammar G; Robertson S; Wedlund L; Lippert M; Rantalainen M; Bergh J; Hartman J
Histopathology; 2018 May; 72(6):974-989. PubMed ID: 29220095
[TBL] [Abstract][Full Text] [Related]
31. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis and cell proliferation in medullary carcinoma of the breast: a comparative study between medullary and non-medullary carcinoma using the TUNEL method and immunohistochemistry.
Kajiwara M; Toyoshima S; Yao T; Tanaka M; Tsuneyoshi M
J Surg Oncol; 1999 Apr; 70(4):209-16. PubMed ID: 10219015
[TBL] [Abstract][Full Text] [Related]
33. Mitotic figure counts are significantly overestimated in resection specimens of invasive breast carcinomas.
Lehr HA; Rochat C; Schaper C; Nobile A; Shanouda S; Vijgen S; Gauthier A; Obermann E; Leuba S; Schmidt M; C CR; Delaloye JF; Simiantonaki N; Schaefer SC
Mod Pathol; 2013 Mar; 26(3):336-42. PubMed ID: 23041831
[TBL] [Abstract][Full Text] [Related]
34. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue.
Laurinavicius A; Plancoulaine B; Laurinaviciene A; Herlin P; Meskauskas R; Baltrusaityte I; Besusparis J; Dasevicius D; Elie N; Iqbal Y; Bor C
Breast Cancer Res; 2014; 16(2):R35. PubMed ID: 24708745
[TBL] [Abstract][Full Text] [Related]
35. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
36. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer.
Thor AD; Liu S; Moore DH; Edgerton SM
J Clin Oncol; 1999 Feb; 17(2):470-7. PubMed ID: 10080587
[TBL] [Abstract][Full Text] [Related]
37. Mitotic index matter: how to improve the assessment of mitosis in order to better classify G2 breast cancer and luminal A category.
Del Sordo R; Bellezza G; Ferri I; Pireddu A; Colella R; Sidoni A
Histol Histopathol; 2018 Jan; 33(1):81-88. PubMed ID: 28332699
[TBL] [Abstract][Full Text] [Related]
38. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
[TBL] [Abstract][Full Text] [Related]
39. Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers.
Wojnar A; Kobierzycki C; Krolicka A; Pula B; Podhorska-Okolow M; Dziegiel P
Folia Histochem Cytobiol; 2010 Sep; 48(3):442-6. PubMed ID: 21097442
[TBL] [Abstract][Full Text] [Related]
40. Expression of proliferation genes in formalin-fixed paraffin-embedded (FFPE) tissue from breast carcinomas. Feasibility and relevance for a routine histopathology laboratory.
Thomas C; Robinson C; Dessauvagie B; Wood B; Sterrett G; Harvey J; Amanuel B
J Clin Pathol; 2017 Jan; 70(1):25-32. PubMed ID: 27235535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
